유방암에서 I123Estradiol 을 이용한 에스트로젠 수용체 스캔의 적용
Imaging of Estrogen Receptors with Iodine-123- Iabeled Estradiol in Primary Breast Cancer Patients
박광인, 노우철, 이령아, 최창운, 방호윤, 황대용, 최동욱, 이종인, 백남선, 문난모,
소속 상세정보
박광인 ( Park Kwang-In )
원자력병원 외과
노우철 ( Noh Woo-Chul )
원자력병원 외과
이령아 ( Lee Ryung-Ah )
원자력병원 외과
최창운 ( Choi Chang-Woon )
원자력의학원 핵의학연구실
방호윤 ( Bang Ho-Yoon )
원자력병원 외과
황대용 ( Hwang Dae-Yong )
원자력병원 외과
최동욱 ( Choi Dong-Wook )
원자력병원 외과
이종인 ( Lee Jong-Inn )
원자력병원 외과
백남선 ( Paik Nam-Sun )
원자력병원 외과
문난모 ( Moon Nan-Mo )
원자력병원 외과
KMID : 0371320020620050366
Abstract
Purpose: We evaluated the feasibility of non-invasive imaging of estrogen receptors (ER) in primary breast cancer with iodine-123-labeled ER specific ligand (17α,20E)-21-[123I] iodo-19-nonpregna-1,3,5-(10), 20-tetraene-3,
17-diol
using conventional nuclear medicine technique.
Methods: Before they underwent surgical management, planar scintigraphy and single-photon emission computed tomography (SPECT) were performed in 18 patients with proven primary breast cancer, after single Ⅳ injection of 5~10 mCi
I-123-estradiol.
The results were compared with those of immunohistochemical staining against ER of the surgical specimens.
Results: Planar and SPECT imaging showed hot uptake in nine of eighteen (50%) breast cancer patients. The results of ER immunohistochemistry were all positive in these patients. In the 9 cases of negative scintigraphy, 8 showed negative
staining
results but one showed positive staining results. Therefore, the overall concordance rate of ER scintigraphy and ER immunohistochemistry was 94.4% (17/18).
Conclusions: ER scintigraphy using I-123-estradiol is a highly predictable in vivo technique to detect ER-positive breast cancer preoperatively. It has potential application as a reliable diagnostic modality and indicator of hormone therapy
for
breast cancer patients.
키워드
유방암; 에스트로겐 수용체; 영상검사법; Breast cancer; Estrogen receptor; Scintigraphy;
원문 및 링크아웃 정보
등재저널 정보